# Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community

> **NCT06704204** · — · NOT_YET_RECRUITING · sponsor: **The Miriam Hospital** · enrollment: 20 (estimated)

## Conditions studied

- HIV

## Interventions

- **DRUG:** The first FDA-approved LAI ART regimen includes an integrase inhibitor, cabotegravir (CAB), and a non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) combined 4 wks

## Key facts

- **NCT ID:** NCT06704204
- **Lead sponsor:** The Miriam Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06704204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06704204, "Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06704204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*